AR068503A1 - Derivados de amidas sustituidas, composicion farmaceutica y usos. - Google Patents
Derivados de amidas sustituidas, composicion farmaceutica y usos.Info
- Publication number
- AR068503A1 AR068503A1 ARP080104094A ARP080104094A AR068503A1 AR 068503 A1 AR068503 A1 AR 068503A1 AR P080104094 A ARP080104094 A AR P080104094A AR P080104094 A ARP080104094 A AR P080104094A AR 068503 A1 AR068503 A1 AR 068503A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- cyclic ring
- och3
- formula
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 7
- 125000004122 cyclic group Chemical group 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97399507P | 2007-09-20 | 2007-09-20 | |
| US5077708P | 2008-05-06 | 2008-05-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068503A1 true AR068503A1 (es) | 2009-11-18 |
Family
ID=40377565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104094A AR068503A1 (es) | 2007-09-20 | 2008-09-19 | Derivados de amidas sustituidas, composicion farmaceutica y usos. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7884108B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2188267B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5485894B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20100072032A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101861307B (cg-RX-API-DMAC7.html) |
| AR (1) | AR068503A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008302099B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0817130A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2700443A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2008002793A1 (cg-RX-API-DMAC7.html) |
| PE (1) | PE20091201A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2470923C2 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI423966B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009039397A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20080839A1 (es) * | 2006-09-11 | 2008-08-23 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas |
| US7838523B2 (en) * | 2006-09-11 | 2010-11-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| US7683064B2 (en) | 2008-02-05 | 2010-03-23 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| EP2297105B1 (en) * | 2008-05-06 | 2015-09-02 | Gilead Connecticut, Inc. | Substituted amides, method of making, and use as btk inhibitors |
| AU2009264400B2 (en) | 2008-06-24 | 2014-05-01 | F. Hoffmann-La Roche Ag | Novel substituted pyridin-2-ones and pyridazin-3-ones |
| HRP20130698T1 (en) | 2008-07-02 | 2013-10-11 | F. Hoffmann - La Roche Ag | Novel phenylpyrazinones as kinase inhibitors |
| MX2012012975A (es) * | 2010-05-07 | 2013-02-26 | Genentech Inc | Compuestos de piridona y aza-piridona y metodos de uso de los mismos. |
| JP5841602B2 (ja) * | 2010-09-01 | 2016-01-13 | ジーアイリード コネチカット インコーポレーテッドＧｉｌｅａｄ Ｃｏｎｎｅｃｔｉｃｕｔ，Ｉｎｃ． | ピリジノン／ピラジノン、その作製方法、および使用方法 |
| WO2013067260A1 (en) | 2011-11-03 | 2013-05-10 | Genentech, Inc. | Bicyclic piperazine compounds |
| CN104203937A (zh) | 2011-11-03 | 2014-12-10 | 霍夫曼-拉罗奇有限公司 | 作为btk活性的抑制剂的8-氟酞嗪-1(2h)-酮化合物 |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| CN104024255B (zh) * | 2011-11-03 | 2017-01-18 | 霍夫曼-拉罗奇有限公司 | 作为btk活性的抑制剂的烷基化哌嗪化合物 |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| EP3366685A1 (en) | 2012-01-09 | 2018-08-29 | X-Chem, Inc. | Tryptoline derivatives having kinase inhibitory activity and uses thereof |
| WO2013157021A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| WO2014108820A1 (en) * | 2013-01-08 | 2014-07-17 | Aurigene Discovery Technologies Limited | Substituted 2-pyrazinone derivatives as kinase inhibitors |
| WO2014125410A1 (en) * | 2013-02-12 | 2014-08-21 | Aurigene Discovery Technologies Limited | N-substituted heterocyclic derivatives as kinase inhibitors |
| CN112047927A (zh) * | 2013-03-15 | 2020-12-08 | 德西费拉制药有限责任公司 | 展现抗癌和抗增殖活性的n-酰基-n′-(吡啶-2-基)脲及类似物 |
| MX367918B (es) | 2013-04-25 | 2019-09-11 | Beigene Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina quinasa. |
| DK3010543T3 (da) * | 2013-06-19 | 2025-12-01 | Som Innovation Biotech S A | Terapeutiske midler til anvendelse i profylakse og/eller behandling af hyperkinetiske bevægelsesforstyrrelser |
| MX2015018038A (es) | 2013-07-03 | 2016-03-16 | Hoffmann La Roche | Compuestos de heteroaril-piridona y aza-piridona-amida. |
| NZ715776A (en) | 2013-07-30 | 2017-04-28 | Gilead Connecticut Inc | Polymorph of syk inhibitors |
| KR20170116203A (ko) | 2013-07-30 | 2017-10-18 | 질레드 코네티컷 인코포레이티드 | Ｓｙｋ 억제제의 제제 |
| HUE060420T2 (hu) | 2013-09-13 | 2023-02-28 | Beigene Switzerland Gmbh | Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk |
| HUE060767T2 (hu) * | 2013-10-18 | 2023-04-28 | Celgene Quanticel Res Inc | Brómdomén inhibitorok |
| ES2716299T3 (es) | 2013-11-20 | 2019-06-11 | Uhde Inventa Fischer Gmbh | Procedimiento así como dispositivo para la preparación de una mezcla de ácido poliláctico cristalizable así como mezcla de ácido poliláctico |
| CN105793251B (zh) | 2013-12-05 | 2018-10-12 | 豪夫迈·罗氏有限公司 | 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物 |
| KR20160093675A (ko) | 2013-12-05 | 2016-08-08 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 키나제의 억제제 |
| TWI735853B (zh) | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | 脾酪胺酸激酶抑制劑 |
| WO2015151006A1 (en) | 2014-03-29 | 2015-10-08 | Lupin Limited | Substituted purine compounds as btk inhibitors |
| WO2015170266A1 (en) | 2014-05-07 | 2015-11-12 | Lupin Limited | Substituted pyrimidine compounds as btk inhibitors |
| CN106660987B (zh) * | 2014-06-27 | 2020-11-06 | 赛尔基因昆蒂赛尔研究公司 | 赖氨酸特异性脱甲基酶-1的抑制剂 |
| EP3164380B1 (en) * | 2014-07-03 | 2022-02-09 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| KR102003754B1 (ko) | 2014-07-03 | 2019-07-25 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
| JP6857606B2 (ja) * | 2015-03-05 | 2021-04-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ブロモドメインｂｒｄ９の阻害剤としての新規ピリジノンおよびイソキノリノン |
| TW201718581A (zh) | 2015-10-19 | 2017-06-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| CA3005727A1 (en) | 2015-11-19 | 2017-05-26 | Incyte Corporation | Substituted 2-methylbiphenyl-3-yl heterocyclic compounds and pharmaceutical compositions thereof useful as immunomodulators |
| CR20180374A (es) | 2015-12-22 | 2018-10-16 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| CN107033069B (zh) | 2016-02-04 | 2022-03-04 | 中国科学院合肥物质科学研究院 | 一种新型布鲁顿酪氨酸激酶不可逆抑制剂 |
| CA3236518A1 (en) | 2016-02-29 | 2017-09-08 | F. Hoffmann-La Roche Ag | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
| UA124764C2 (uk) | 2016-04-15 | 2021-11-17 | Еббві Інк. | Інгібітори бромодомену |
| MA44860A (fr) | 2016-05-06 | 2019-03-13 | Incyte Holdings Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CA3028685A1 (en) * | 2016-06-20 | 2017-12-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018007885A1 (en) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
| WO2018013789A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| AU2017314178B2 (en) | 2016-08-16 | 2021-11-18 | Beone Medicines I Gmbh | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| PT3500299T (pt) | 2016-08-19 | 2024-02-21 | Beigene Switzerland Gmbh | Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| US20190201409A1 (en) | 2016-09-19 | 2019-07-04 | Mei Pharma, Inc. | Combination therapy |
| JP7038712B2 (ja) * | 2016-11-22 | 2022-03-18 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｂｔｋの分解および使用法 |
| US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG10202106743QA (en) | 2016-12-22 | 2021-08-30 | Incyte Corp | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
| ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| CR20190318A (es) | 2016-12-22 | 2019-10-21 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| JP7303108B2 (ja) | 2016-12-22 | 2023-07-04 | インサイト・コーポレイション | 免疫調節剤としての二環式複素芳香環化合物 |
| CN110139641B (zh) * | 2016-12-28 | 2022-09-09 | 富士胶片富山化学株式会社 | 外用组合物 |
| EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES |
| JP2020514384A (ja) | 2017-03-24 | 2020-05-21 | ジェネンテック， インコーポレイテッド | 自己免疫及び炎症性疾患を治療する方法 |
| TWI877099B (zh) | 2017-06-26 | 2025-03-21 | 英屬開曼群島商百濟神州有限公司 | 抗ｐｄ－１抗體或其抗原結合片段在製備治療用於患有肝細胞癌（ｈｃｃ）之藥物的用途 |
| WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY |
| WO2019040298A1 (en) | 2017-08-25 | 2019-02-28 | Gilead Sciences, Inc. | SYK INHIBITORY POLYMORPHS |
| KR102613433B1 (ko) | 2017-10-11 | 2023-12-13 | 주식회사 대웅제약 | 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물 |
| CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
| US11712458B2 (en) | 2018-01-29 | 2023-08-01 | Dana-Farber Cancer Institute, Inc. | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use |
| EP4212529B1 (en) | 2018-03-30 | 2025-01-29 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP4520328A3 (en) | 2018-05-11 | 2025-04-16 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US11339168B2 (en) | 2019-02-22 | 2022-05-24 | Kronos Bio, Inc. | Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors |
| CN113939289A (zh) | 2019-06-10 | 2022-01-14 | 百济神州瑞士有限责任公司 | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 |
| WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| CR20220190A (es) | 2019-09-30 | 2022-06-15 | Incyte Corp | Compuestos de pirido [3,2-d] primidina como inmunomoduladores |
| EP4058461A1 (en) | 2019-11-11 | 2022-09-21 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| WO2021093817A1 (zh) * | 2019-11-15 | 2021-05-20 | 杭州和正医药有限公司 | 免疫调节化合物、组合物及其应用 |
| CN114380841B (zh) * | 2020-10-19 | 2025-12-30 | 南京正大天晴制药有限公司 | 作为akt抑制剂的三环喹唑啉或二氢喹唑啉化合物 |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| PE20231438A1 (es) | 2020-11-06 | 2023-09-14 | Incyte Corp | Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| WO2005014599A1 (en) * | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| JP2008533032A (ja) * | 2005-03-10 | 2008-08-21 | シージーアイ ファーマシューティカルズ，インコーポレイティド | 或る種の置換アミド、その製造方法及び使用方法 |
| PE20080839A1 (es) * | 2006-09-11 | 2008-08-23 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas |
| WO2008033858A2 (en) | 2006-09-11 | 2008-03-20 | Cgi Pharmaceuticals, Inc. | Kinase inhibitors, and methods of using and identifying kinase inhibitors |
-
2008
- 2008-09-17 CL CL2008002793A patent/CL2008002793A1/es unknown
- 2008-09-19 BR BRPI0817130 patent/BRPI0817130A2/pt not_active Application Discontinuation
- 2008-09-19 JP JP2010526003A patent/JP5485894B2/ja active Active
- 2008-09-19 TW TW097136216A patent/TWI423966B/zh not_active IP Right Cessation
- 2008-09-19 PE PE2008001640A patent/PE20091201A1/es not_active Application Discontinuation
- 2008-09-19 AU AU2008302099A patent/AU2008302099B2/en not_active Ceased
- 2008-09-19 CA CA2700443A patent/CA2700443A1/en not_active Abandoned
- 2008-09-19 CN CN2008801161200A patent/CN101861307B/zh active Active
- 2008-09-19 EP EP08832237.5A patent/EP2188267B1/en active Active
- 2008-09-19 WO PCT/US2008/077054 patent/WO2009039397A2/en not_active Ceased
- 2008-09-19 KR KR1020107008468A patent/KR20100072032A/ko not_active Withdrawn
- 2008-09-19 US US12/234,281 patent/US7884108B2/en active Active
- 2008-09-19 AR ARP080104094A patent/AR068503A1/es unknown
- 2008-09-19 RU RU2010115574/04A patent/RU2470923C2/ru active
-
2010
- 2010-11-04 US US12/939,518 patent/US8247550B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010540452A (ja) | 2010-12-24 |
| US7884108B2 (en) | 2011-02-08 |
| RU2470923C2 (ru) | 2012-12-27 |
| WO2009039397A3 (en) | 2009-05-22 |
| BRPI0817130A2 (pt) | 2015-03-31 |
| KR20100072032A (ko) | 2010-06-29 |
| EP2188267A2 (en) | 2010-05-26 |
| US20110059944A1 (en) | 2011-03-10 |
| US20090082330A1 (en) | 2009-03-26 |
| AU2008302099A1 (en) | 2009-03-26 |
| CN101861307B (zh) | 2013-05-01 |
| CN101861307A (zh) | 2010-10-13 |
| US8247550B2 (en) | 2012-08-21 |
| RU2010115574A (ru) | 2011-10-27 |
| EP2188267B1 (en) | 2016-08-03 |
| TW200914446A (en) | 2009-04-01 |
| WO2009039397A2 (en) | 2009-03-26 |
| CA2700443A1 (en) | 2009-03-26 |
| CL2008002793A1 (es) | 2009-09-04 |
| TWI423966B (zh) | 2014-01-21 |
| PE20091201A1 (es) | 2009-09-13 |
| AU2008302099B2 (en) | 2013-03-28 |
| JP5485894B2 (ja) | 2014-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR068503A1 (es) | Derivados de amidas sustituidas, composicion farmaceutica y usos. | |
| AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR078152A1 (es) | Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden | |
| CL2011002859A1 (es) | Compuestos espironucleosidos, inhibidores del virus vhc; composicion farmaceutica de dichos compuestos; uso del compuesto para tratar la hepatitis c. | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR080187A1 (es) | Derivados pirazolicos condensados con heterociclos nitrogenados utiles en el tratamiento de enfermedades inflamatorias, inmunitarias y/o trastornos mieloploliferativos y composiciones farmaceuticas que los contienen. | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| CO5690588A2 (es) | Derivados de 4-tetrazolilo-4 fenilpiperidina para el trata- miento del dolor | |
| AR064471A1 (es) | Macrociclos inhibidores selectivos del factor de coagulacion viia, composiciones farmaceuticas que los comprenden y uso de los mismos como agentes anticoagulantes. | |
| AR085489A1 (es) | Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias | |
| RU2011116160A (ru) | Производные пиридина, замещенные гетероциклическим кольцом и y-глутамиламиногруппой и содержащие их противогрибковые средства | |
| AR035580A1 (es) | Compuestos inhibidores de ifata, compuestos intermediarios, procedimientos de preparacion y su uso en la preparacion de medicamentos | |
| SI2310396T1 (en) | Macrocyclic derivatives of indole are useful as inhibitors of hepatitis C virus | |
| AR019190A1 (es) | Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos | |
| AR077525A1 (es) | 4-aril-butan-1,3-diamidas y composiciones farmaceuticas | |
| AR072301A1 (es) | Derivados de acido fenoxicroman carboxilico 6-sustituido utiles en el tratamiento y/o prevencion de enfermedades alergicas e inflamatorias, composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos y compuestos intermediarios. | |
| ES2530815T3 (es) | Tiazolil y oxazolil-isoquinolinonas y métodos para usar las mismas | |
| AR080253A1 (es) | Inhibidores dimericos de las iap (proteinas inhibidoras de la apoptosis) | |
| AR068695A2 (es) | Uso de un compuesto de tiazol que comprende un derivado de tiazol para la fabricacion de un medicamento para la prevencion y el tratamiento de en-fermedades causadas por la produccion anormal de citocinas y/o la acele-racion de la adhesion de neutrofilos y/o la produccion anormal de tnf- alfa | |
| AR071619A1 (es) | Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias y composiciones farmaceuticas que los contienen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |